

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of ALS and HTICI referred to in this announcement.*



**信銘生命科技集團有限公司**  
**Aceso Life Science Group Limited**

*(formerly known as Hao Tian Development Group Limited 昊天發展集團有限公司)*  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00474)**

**HAO TIAN INTERNATIONAL**  
**CONSTRUCTION INVESTMENT GROUP LIMITED**

**昊天國際建設投資集團有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1341)**

## **JOINT ANNOUNCEMENT**

**COMPLETION OF  
DISCLOSEABLE TRANSACTION  
IN RELATION TO  
(A) ACQUISITION OF SALE SHARES  
INVOLVING ISSUE OF  
CONSIDERATION SHARES  
BY SUBSIDIARY UNDER GENERAL  
MANDATE  
AND  
(B) DEEMED DISPOSAL**

**COMPLETION OF  
DISCLOSEABLE TRANSACTION  
IN RELATION TO  
ACQUISITION OF SALE SHARES  
INVOLVING ISSUE OF  
CONSIDERATION SHARES  
UNDER GENERAL MANDATE**

Reference is made to the joint announcements (the “**Joint Announcements**”) of Aceso Life Science Group Limited (“**ALS**”) and Hao Tian International Construction Investment Group Limited (“**HTICI**”) dated 26 April 2021, 7 May 2021 and 14 May 2021 in respect of the discloseable transaction in relation to the acquisition of Sale Shares in the Target Company involving issue of Consideration Shares by HTICI under the General Mandate, which constitutes a deemed disposal by ALS. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Joint Announcements.

Each of the ALS Board and HTICI Board is pleased to announce that all conditions precedent under the Agreement have been fulfilled and the Completion took place on 20 May 2021. Upon Completion, the Purchaser owns 49% of the entire issued share capital of the Target Company. The Target Company is treated as an associate of the ALS Group and HTICI Group and therefore its financial results will be accounted for using equity method in the financial statements of each of the ALS Group and HTICI Group.

In accordance with terms and conditions of the Agreement, HTICI has allotted and issued 867,383,524 Consideration Shares to the Vendor.

The shareholding structure of HTICI immediately before and after Completion is as follows:

Name of shareholders	Immediately before the Completion		Immediately after the Completion	
	Number of HTICI Shares	Approximate %	Number of HTICI Shares	Approximate %
ALS ( <i>note 1</i> )	3,545,725,259	53.24%	3,545,725,259	47.06%
Lin Yuan ( <i>note 2</i> )	1,000,000,000	15.02%	1,000,000,000	13.27%
Vendor	0	0.00%	867,383,524	11.51%
<b>Public</b>				
Other public shareholders	2,113,657,873	31.74%	2,122,157,871 <i>(Note 3)</i>	28.16%
Total	6,659,383,132	100.00%	7,535,266,654 <i>(Note 3)</i>	100.00%

*Notes:*

- As at the date of this announcement, ALS, which is an indirect controlling shareholder of HTICI, is interested in an aggregate of 3,545,725,259 HTICI Shares, comprising of (i) 2,688,944,688 HTICI Shares through its wholly-owned companies Win Team Investments Limited and Hao Tian Management (China) Limited; (ii) 785,352,000 HTICI Shares through its wholly-owned company Win Team Investments Limited and non-wholly owned subsidiary Hao Tian Management (Hong Kong) Limited; and (iii) 71,428,571 HTICI Shares through its wholly-owned companies Guo Guang Limited and Hao Tian Finance Company Limited.
- According to the information available, Ms. Lin is beneficially interested in a total of 1,000,000,000 HTICI Shares, among which, 500,000,000 HTICI Shares are held by Ms. Lin as beneficial owner, and 500,000,000 HTICI Shares are shares held by Soaring Wealth Ventures Limited which is wholly-owned by Ms. Lin.
- HTICI issued 8,499,998 new HTICI Shares on 20 May 2021 under its share award scheme.

ALS remains control over HTICI after the Deemed Disposal. Accordingly, HTICI remains as an indirect non-wholly owned subsidiary of ALS and its financial results, assets, liabilities and cash flows will continue to be consolidated into the ALS's consolidated financial statements.

By order of the board of directors of  
**Aceso Life Science Group Limited**  
**Fok Chi Tak**  
*Executive Director*

By order of the board of directors of  
**Hao Tian International Construction**  
**Investment Group Limited**  
**Fok Chi Tak**  
*Executive Director*

Hong Kong, 20 May 2021

*As at the date of this announcement, the ALS Board comprises three executive directors, namely Mr. Xu Haiying, Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; two non-executive directors, namely Dr. Wang Yu and Dr. Li Yao; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Lee Chi Hwa Joshua.*

*As at the date of this announcement, the HTICI Board comprises four executive directors, namely Mr. Fok Chi Tak, Mr. Zheng Li, Mr. Tang Yiu Chi James and Dr. Zhiliang Ou, J.P. (Australia); two non-executive directors, namely Mr. Xu Lin and Mr. Wei Bin; and four independent non-executive directors, namely Mr. Lee Chi Hwa Joshua, Mr. Mak Yiu Tong, Mr. Li Chi Keung Eliot and Mr. Shek Lai Him Abraham.*